GAL and metabolic dysfunction-associated steatotic liver disease: Additionally, Gal-LNP-RSV restored the liver-to-body weight ratio to baseline levels (Fig. 7D) and reduced hepatic lipid accumulation, TG content, and TC content by 43.6%, 49.1%, and 33.5%, respectively, compared with the NAFLD model (p < 0.05), outperforming LNP-RSV (32.3%, 29.8%, and 27.2%, respectively) (Fig. 7H–I).